Advancements in Bi-Specific Antibodies for Solid Tumors

Exploring the challenges of developing therapies for solid tumors, focusing on next-generation CD3 bispecific antibodies, co-stimulatory receptors, and specific indications like bladder cancer. Delving into the complexity of solid tumors and the emerging trend of combination therapies for safe and effective dosing. Discussing the comparison between bispecific antibodies and other modalities, emphasizing their potential in addressing relapses and the importance of exploring different targets for maximum efficacy.